Polarean to be a featured company at 2023 ATS Respiratory Innovation Summit
03 mai 2023 12h34 HE
|
Polarean Imaging plc
Durham, N.C., May 03, 2023 (GLOBE NEWSWIRE) -- Polarean Imaging plc (AIM: POLX), the medical imaging technology company, has been selected as one of the featured companies as a poster presenter at...
aTyr Pharma to Present Clinical Data for Efzofitimod (ATYR1923) at the American Thoracic Society 2022 International Conference
01 avr. 2022 08h00 HE
|
aTyr Pharma, Inc.
Results from Phase 1b/2a study of efzofitimod in pulmonary sarcoidosis patients demonstrate safety and dose dependent trends of improvement compared to placebo for key efficacy endpoints. Efzofitimod...
Survey Reveals Majority of Patients Diagnosed with Chronic Pulmonary Disorders Are Unaware of Standard-of-Care Treatment for Their Deadly Disease
12 nov. 2018 09h24 HE
|
American Thoracic Society
Chronic respiratory diseases – primarily COPD – are the third leading cause of death, yet 62 percent of patients have not heard of pulmonary rehabilitation NEW YORK, Nov. 12, 2018 (GLOBE NEWSWIRE)...
Initial Clinical Results of Konica Minolta Healthcare’s Dynamic Digital Radiography Presented at ATS 2018 Annual Meeting
24 mai 2018 10h32 HE
|
Konica Minolta Healthcare Americas, Inc.
WAYNE, N.J., May 24, 2018 (GLOBE NEWSWIRE) -- Konica Minolta Healthcare Americas, Inc., announced that two clinical studies utilizing Dynamic Digital Radiography (DDR), the company’s innovative...
Cempra Presenting Additional Data From the Phase 3 Oral Solithromycin Study in Community Acquired Bacterial Pneumonia at the American Thoracic Society Conference
19 mai 2015 07h00 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 19, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
Cempra to Present Solithromycin Data at Two Upcoming Medical Conferences
12 mai 2015 07h30 HE
|
Melinta Therapeutics, Inc.
CHAPEL HILL, N.C., May 12, 2015 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the...
CPF Celebrates Historic Year of Progress in Pulmonary Fibrosis
30 déc. 2014 14h05 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Dec. 30, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) played an important role in much of the year's successes in Pulmonary Fibrosis (PF), helping to make...
CPF Applauds Two FDA Approvals Announced Today for First Drugs for Idiopathic Pulmonary Fibrosis
15 oct. 2014 18h02 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, CALIF., Oct. 15, 2014 (GLOBE NEWSWIRE) -- The Coalition for Pulmonary Fibrosis (CPF) applauds the two U.S. Food and Drug Administration (FDA) approvals announced today for Idiopathic...
FDA Chooses Four CPF Advocates to Speak on IPF Workshop Panel
25 sept. 2014 12h45 HE
|
Coalition for Pulmonary Fibrosis (CPF)
DISTRICT OF COLUMBIA, Wash., Sept. 25, 2014 (GLOBE NEWSWIRE) -- Four of the eight panelist to address the FDA tomorrow at the first U.S. Food and Drug Administration (FDA) workshop on Idiopathic...
September Most Important Month in History for U.S. Patients Suffering from Idiopathic Pulmonary Fibrosis: FDA Workshop, Impending Drug Decisions, PF Month Activities
11 sept. 2014 16h14 HE
|
Coalition for Pulmonary Fibrosis (CPF)
CULVER CITY, Calif., Sept. 11, 2014 (GLOBE NEWSWIRE) -- Never before have there been so many opportunities for patients to be heard regarding a deadly lung disease than this month: the U.S. Food and...